Morgan Stanley Maintains Overweight on Nasdaq, Raises Price Target to $245

Morgan Stanley analyst Michael Cyprys maintains Nasdaq (NASDAQ:NDAQ) with a Overweight and raises the price target from $238 to $245.

byBenzinga Newsdesk

April 13, 2022

1 minute read

Morgan Stanley analyst Michael Cyprys maintains Nasdaq (NASDAQ:NDAQ) with a Overweight and raises the price target from $238 to $245.

Keybanc Upgrades VICI Properties to Overweight, Announces $33 Price Target

By Benzinga Newsdesk

Today, 3:21 AM

Keybanc analyst Todd Thomas upgrades VICI Properties (NYSE:VICI) from Sector Weight to Overweight and announces $33 price target.

VICI

News

Enphase Energy Reports Renewal Of Partnership With GRID Alternatives To Increase Access To Solar, No Terms Disclosed

By Benzinga Newsdesk

Today, 3:21 AM

Enphase Energy, Inc. (NASDAQ:ENPH), a global energy management technology company and the world’s leading supplier of microinverter-based solar-plus-storage systems, announced today that it has renewed its

ENPH

News

Kazia Therapeutics Announced Manufacturing Patents Granted for Paxalisib in Key Territories; Extend Effective Patent Protection to 2036

By Charles Gross

Today, 3:21 AM

Kazia Therapeutics Limited (NASDAQ: KZIA) is pleased to announce the grant of patents by the respective agencies of the United States and India in respect of the manufacturing process for paxalisib. A similar patent has been accepted in Australia and is expected to proceed to grant in 3Q CY2021.

KZIA